Intuitive Surgical Inc Stock (ISRG) Moved Down by 3.28% on May 27: Drivers Behind the Movement

Intuitive Surgical Inc (ISRG) moved down by 3.28%. The Healthcare Services & Equipment sector is down by 0.34%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Boston Scientific Corp (BSX) down 10.67%; Unitedhealth Group Inc (UNH) up 1.73%; Intuitive Surgical Inc (ISRG) down 3.28%.

What is driving Intuitive Surgical Inc (ISRG)’s stock price down today?

Intuitive Surgical (ISRG) experienced a share price decrease due to significant product recalls impacting its core da Vinci surgical systems. The US FDA announced a Class I recall in May 2026 for SureForm 30 Gray Reloads, citing incomplete staple lines, alongside additional recalls involving da Vinci X and Xi system components due to screw breakage risks. These events have intensified investor concerns regarding product reliability, safety perceptions, and potential future regulatory oversight, especially given the da Vinci platforms are central to the company's business.

The recalls compound existing market sentiment, as the stock has already shown weaker performance over the past month and year-to-date. In response to these developments and a reassessment of the company's valuation, several analyst firms have recently adjusted their price targets downwards. Goldman Sachs, for example, reduced its target while maintaining a buy rating. Bank of America also lowered its target, among others. These downward revisions from analysts have amplified discussions around the stock's premium valuation.

Indeed, recent analyses suggest the company's stock is significantly overvalued when assessed using discounted cash flow models. This valuation concern, coupled with the product recall news, is contributing to investor caution. While the company recently reported strong first-quarter financial results, including a substantial increase in revenue and da Vinci procedure growth, and announced ongoing innovations, these positive factors appear to be overshadowed by the regulatory and product reliability issues. Institutional investor activity has been mixed, with some firms increasing their holdings while others have trimmed positions, indicating a selective approach to the stock amidst its demanding valuation.

Technical Analysis of Intuitive Surgical Inc (ISRG)

Technically, Intuitive Surgical Inc (ISRG) shows a MACD (12,26,9) value of [-7.72], indicating a neutral signal. The RSI at 43.82 suggests neutral condition and the Williams %R at -57.68 suggests oversold condition. Please monitor closely.

Media Coverage of Intuitive Surgical Inc (ISRG)

In terms of media coverage, Intuitive Surgical Inc (ISRG) shows a coverage score of 49, indicating a moderate level of media attention. The overall market sentiment index is currently in bullish zone.

Fundamental Analysis of Intuitive Surgical Inc (ISRG)

Intuitive Surgical Inc (ISRG) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $10.06B, ranking 15 in the industry. The net profit is $2.86B, ranking 7 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $579.11, a high of $750.00, and a low of $440.00.

More details about Intuitive Surgical Inc (ISRG)

Company Specific Risks:

• Multiple voluntary product recalls for da Vinci systems and instruments, including a Class I recall for SureForm 30 Gray Reloads due to incomplete staple lines, heighten regulatory scrutiny and pose risks to product reliability and adoption.
• Intensifying competition from new market entrants and specialized rivals is leading to aggressive pricing pressures, elongated negotiation timelines, and potential erosion of market share in various surgical segments.
• A recent Washington state court ruling denied the company's motion to dismiss a product liability lawsuit, underscoring ongoing legal exposure related to patient outcomes and the requirement for robust physician training on da Vinci systems.
• Anticipated tariffs are projected to negatively impact non-GAAP gross profit margins by 100 basis points in 2026, potentially affecting demand and profitability, particularly in crucial international markets.